Literature DB >> 19507261

Mutations of key hydrophobic surface residues of 11 beta-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression system.

Alexander J Lawson1, Elizabeth A Walker, Scott A White, Timothy R Dafforn, Paul M Stewart, Jonathan P Ride.   

Abstract

11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is a key enzyme in the conversion of cortisone to the functional glucocorticoid hormone cortisol. This activation has been implicated in several human disorders, notably the metabolic syndrome where 11 beta-HSD1 has been identified as a novel target for potential therapeutic drugs. Recent crystal structures have revealed the presence of a pronounced hydrophobic surface patch lying on two helices at the C-terminus. The physiological significance of this region has been attributed to facilitating substrate access by allowing interactions with the endoplasmic reticulum membrane. Here, we report that single mutations that alter the hydrophobicity of this patch (I275E, L266E, F278E, and L279E in the human enzyme and I275E, Y266E, F278E, and L279E in the guinea pig enzyme) result in greatly increased yields of soluble protein on expression in E. coli. Kinetic analyses of both reductase and dehydrogenase reactions indicate that the F278E mutant has unaltered K(m) values for steroids and an unaltered or increased k(cat). Analytical ultracentrifugation shows that this mutation also decreases aggregation of both the human and guinea pig enzymes, resulting in greater monodispersity. One of the mutants (guinea pig F278E) has proven easy to crystallize and has been shown to have a virtually identical structure to that previously reported for the wild-type enzyme. The human F278E enzyme is shown to be a suitable background for analyzing the effects of naturally occurring mutations (R137C, K187N) on enzyme activity and stability. Hence, the F278E mutants should be useful for many future biochemical and biophysical studies of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19507261      PMCID: PMC2775222          DOI: 10.1002/pro.150

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  38 in total

Review 1.  Forms and functions of human SDR enzymes.

Authors:  U C Oppermann; C Filling; H Jörnvall
Journal:  Chem Biol Interact       Date:  2001-01-30       Impact factor: 5.192

2.  11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase.

Authors:  Edmund Maser; Bernhard Völker; Jutta Friebertshäuser
Journal:  Biochemistry       Date:  2002-02-19       Impact factor: 3.162

3.  Human 11beta-hydroxysteroid dehydrogenase type 1 is enzymatically active in its nonglycosylated form.

Authors:  A Blum; H J Martin; E Maser
Journal:  Biochem Biophys Res Commun       Date:  2000-09-24       Impact factor: 3.575

4.  Structural role of conserved Asn179 in the short-chain dehydrogenase/reductase scaffold.

Authors:  C Filling; E Nordling; J Benach; K D Berndt; R Ladenstein; H Jörnvall; U Oppermann
Journal:  Biochem Biophys Res Commun       Date:  2001-12-07       Impact factor: 3.575

5.  A transgenic model of visceral obesity and the metabolic syndrome.

Authors:  H Masuzaki; J Paterson; H Shinyama; N M Morton; J J Mullins; J R Seckl; J S Flier
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

6.  Functional expression, characterization, and purification of the catalytic domain of human 11-beta -hydroxysteroid dehydrogenase type 1.

Authors:  E A Walker; A M Clark; M Hewison; J P Ride; P M Stewart
Journal:  J Biol Chem       Date:  2001-04-06       Impact factor: 5.157

7.  Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.

Authors:  N M Morton; M C Holmes; C Fiévet; B Staels; A Tailleux; J J Mullins; J R Seckl
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

8.  Critical residues for structure and catalysis in short-chain dehydrogenases/reductases.

Authors:  Charlotta Filling; Kurt D Berndt; Jordi Benach; Stefan Knapp; Tim Prozorovski; Erik Nordling; Rudolf Ladenstein; Hans Jörnvall; Udo Oppermann
Journal:  J Biol Chem       Date:  2002-04-25       Impact factor: 5.157

9.  Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.

Authors:  B Ganesh Bhat; Natilie Hosea; Andrea Fanjul; Jocelyn Herrera; Justin Chapman; Fred Thalacker; Paul M Stewart; Paul A Rejto
Journal:  J Pharmacol Exp Ther       Date:  2007-10-05       Impact factor: 4.030

10.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

Authors:  P A Williams; J Cosme; V Sridhar; E F Johnson; D E McRee
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

View more
  4 in total

Review 1.  Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery.

Authors:  Mark P Thomas; Barry V L Potter
Journal:  Future Med Chem       Date:  2011-03       Impact factor: 3.808

2.  Post-production protein stability: trouble beyond the cell factory.

Authors:  Esther Vazquez; José Luis Corchero; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2011-08-01       Impact factor: 5.328

3.  Surface patches on recombinant erythropoietin predict protein solubility: engineering proteins to minimise aggregation.

Authors:  M Alejandro Carballo-Amador; Edward A McKenzie; Alan J Dickson; Jim Warwicker
Journal:  BMC Biotechnol       Date:  2019-05-09       Impact factor: 2.563

4.  Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Alexander J Lawson; Elizabeth A Walker; Gareth G Lavery; Iwona J Bujalska; Beverly Hughes; Wiebke Arlt; Paul M Stewart; Jonathan P Ride
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.